Utility of Genome-Wide Association Studies in Pediatric Oncology

Zhaoming Wang, PhD
Published: Wednesday, Nov 28, 2018



Zhaoming Wang, PhD, bioinformatics scientist, Department of Computational Biology, St. Jude Children’s Research Hospital, discusses the utility of genome-wide association studies in pediatric oncology.

The monogenic and polygenic associations to subsequent breast cancer risk in survivors of childhood cancer is currently being studied using whole-genome sequencing data. Although genome-wide associated studies like this have been successful, some in the community have doubts over their clinical utility, Wang says. Although more data are needed to support a clinical recommendation, this is the first instance in which evidence to support common variant effects were found in childhood survivors of cancer.

Wang explains that using a bigger sample size gives a greater picture of what is occurring in these patients. Additionally, Wang says that this is an era in which data like these can be clinically combined with rare mutations that can explain a lot of heritable breast cancers, rather than sporadic. Science is progressing, and there is promise in finding and managing high-risk patients for screening and cancer prevention at early stages.
SELECTED
LANGUAGE


Zhaoming Wang, PhD, bioinformatics scientist, Department of Computational Biology, St. Jude Children’s Research Hospital, discusses the utility of genome-wide association studies in pediatric oncology.

The monogenic and polygenic associations to subsequent breast cancer risk in survivors of childhood cancer is currently being studied using whole-genome sequencing data. Although genome-wide associated studies like this have been successful, some in the community have doubts over their clinical utility, Wang says. Although more data are needed to support a clinical recommendation, this is the first instance in which evidence to support common variant effects were found in childhood survivors of cancer.

Wang explains that using a bigger sample size gives a greater picture of what is occurring in these patients. Additionally, Wang says that this is an era in which data like these can be clinically combined with rare mutations that can explain a lot of heritable breast cancers, rather than sporadic. Science is progressing, and there is promise in finding and managing high-risk patients for screening and cancer prevention at early stages.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x